期刊
BRITISH JOURNAL OF CANCER
卷 121, 期 5, 页码 405-416出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41416-019-0531-5
关键词
-
类别
资金
- Assistance Publique Hopitaux de Paris
- La Ligue Contre le Cancer
- Conseil Regional de Franche-Comte
- Canceropole Grand Est
BACKGROUND: Despite the critical roles of Th1-polarised CD4(+) T cells in cancer immunosurveillance, the translation of their potential to clinical use remains challenging. Here, we investigate the clinical relevance of circulating antitumor Th1 immunity in non-small cell lung cancer (NSCLC). METHODS: The circulating antitumor Th1 response was assessed by the ELISpot assay in 170 NSCLC patients using a mixture of HLA class II-restricted peptides from telomerase (TERT). Phenotyping of blood immune cells was performed by flow cytometry. RESULTS: TERT-reactive CD4 T-cell response was detected in 35% of NSCLC patients before any treatment. Functional analysis showed that these cells were effector memory and Th1 polarised capable to produce effector cytokines, such as IFN-gamma, TNF-alpha and IL-2. The presence of anti-TERT Th1 response was inversely correlated with the level of exhausted PD-1(+)/TIM-3(+)CD4 T cells. The level of these two immune parameters differentially affected the survival, so that increased level of anti-TERT Th1 response and low rate of exhausted PD-1(+)TIM-3(+)CD4(+) T cells were associated with a better prognosis. CONCLUSIONS: Systemic anti-TERT Th1 response plays a strong antitumor protective role in NSCLC. This study underlines the potential interest of monitoring circulating antitumor Th1 response for patients' stratification and therapy decision.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据